Stocks and Investing
Stocks and Investing
Mon, January 29, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Balaji Prasad Maintained (AMRX) at Buy with Increased Target to $8 on, Jan 29th, 2024
Balaji Prasad of Barclays, Maintained "Amneal Pharmaceuticals, Inc." (AMRX) at Buy with Increased Target from $6 to $8 on, Jan 29th, 2024.
Balaji has made no other calls on AMRX in the last 4 months.
There is 1 other peer that has a rating on AMRX. Out of the 1 peers that are also analyzing AMRX, 0 agree with Balaji's Rating of Hold.
This is the rating of the analyst that currently disagrees with Balaji
- Gregory Fraser of "Truist Securities" Maintained at Strong Buy with Increased Target to $7 on, Wednesday, November 8th, 2023
Contributing Sources